Antifungal Application of Nonantifungal Drugs

Stylianou, Marinos; Kulesskiy, Evgeny; Lopes, José Pedro; Granlund, Margareta; Wennerberg, Krister; Urban, Constantin F.

doi:10.1128/aac.01087-13

Cited by 58 publications

(52 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous report has suggested that C. albicans and C. glabrata have susceptibility to auranofin [35]. Notably, C. neoformans was inhibited at a low MIC that was reduced even further by oxide stressors.…”

Section: Discussionmentioning

confidence: 77%

Inhibition of Bacterial and Fungal Pathogens by the Orphaned Drug Auranofin

et al. 2016

View full text Add to dashboard Cite

Background:We identified auranofin as an antimicrobial compound utilizing a highthroughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 μg/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 μg/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.

show abstract

Section: Discussionmentioning

confidence: 77%

Inhibition of Bacterial and Fungal Pathogens by the Orphaned Drug Auranofin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The fungicidal activity of CeO 2 NPs was found to be maximum in the case of Mucor species with ZOI of 22 mm, showing great competency as an antifungal agent, like other antifungal candidates. 41 The Figure 11 schematic illustration of ceO 2 NPs antibacterial activity. Abbreviations: NPs, nanoparticles; rOs, reactive oxygen species.…”

Section: Antifungal Assay Analysis Of Ceo 2 Npsmentioning

confidence: 99%

Antimicrobial potential of green synthesized CeO2 nanoparticles from Olea europaea leaf extract

Maqbool

Nazar

Naz

et al. 2016

IJN

149

101

View full text Add to dashboard Cite

This article reports the green fabrication of cerium oxide nanoparticles (CeO 2 NPs) using Olea europaea leaf extract and their applications as effective antimicrobial agents. O. europaea leaf extract functions as a chelating agent for reduction of cerium nitrate. The resulting CeO 2 NPs exhibit pure single-face cubic structure, which is examined by X-ray diffraction, with a uniform spherical shape and a mean size 24 nm observed through scanning electron microscopy and transmission electron microscopy. Ultraviolet-visible spectroscopy confirms the characteristic absorption peak of CeO 2 NPs at 315 nm. Fourier transform infrared spectroscopy reflects stretching frequencies at 459 cm −1 , showing utilization of natural components for the production of NPs. Thermal gravimetric analysis predicts the successful capping of CeO 2 NPs by bioactive molecules present in the plant extract. The antimicrobial studies show significant zone of inhibition against bacterial and fungal strains. The higher activities shown by the green synthesized NPs than the plant extract lead to the conclusion that they can be effectively used in biomedical application. Furthermore, reduction of cerium salt by plant extract will reduce environmental impact over chemical synthesis.

show abstract

“…The various associations tested the most common are those where fluconazole is used as a prototype Stylianou et al, 2014). In our work we used a widely used antifungal miconazole and rarely described when evaluating synergy.…”

Section: Discussionmentioning

confidence: 99%

In vitro synergistic activity of lidocaine and miconazole against Candida albicans

Cunha¹,

Filho²,

Cunha³

et al. 2017

Acta Sci. Health Sci.

View full text Add to dashboard Cite

ABSTRACT. Candida albicans is the main yeast isolated from vulvovaginal candidiasis(VVC) and a major antifungal used to treat VVC is miconazole (MZ), it shows local toxic effects, such as irritation and burns. The lidocaine (LD) is a local anesthetic. The aim of this study was to evaluate the synergistic activity of LD/MZ against 19 strains of C. albicans isolated from vaginal secretion. 78.9% of the strains were susceptible to the combination LD/MZ, demonstrating synergism of drugs. These drugs can be used to produce vaginal creams to treat VVC, especially drug resistant.Keywords: vulvovaginal candidiasis, antifungal agents, local anesthetic.Atividade sinérgica in vitro de lidocaína e miconazole contra Candida albicans RESUMO. Candida albicans é a principal levedura isolada de candidíase vulvovaginal (CVV) e o principal antifúngico usado para tratar a VVC é miconazol (MZ), que apresenta efeitos tóxicos locais, tais como irritação e queimaduras. A lidocaína (LD) é um anestésico local. O objetivo deste estudo foi avaliar a atividade sinérgica de LD/MZ contra 19 cepas de C. albicans isoladas de secreção vaginal. Foram suscetíveis à combinação LD/MZ, 78.9% das cepas testadas, demonstrando sinergismo de drogas. Estes fármacos podem ser utilizados para a produção de cremes vaginais para tratar VVC, especialmente aquelas resistentes aos fármacos disponíveis.Palavras-chave: candidíase vulvovaginal, agentes antifúngicos, anestésico local.

show abstract

Antifungal Application of Nonantifungal Drugs

Cited by 58 publications

References 51 publications

Inhibition of Bacterial and Fungal Pathogens by the Orphaned Drug Auranofin

Inhibition of Bacterial and Fungal Pathogens by the Orphaned Drug Auranofin

Antimicrobial potential of green synthesized CeO<sub>2</sub> nanoparticles from <em>Olea europaea</em> leaf extract

<b><i>In vitro</i> synergistic activity of lidocaine and miconazole against <i>Candida albicans

Contact Info

Product

Resources

About